Key result
Cycle-synchronized crocus total glucosides reduce 6-month LVGLS decline by ~48% versus placebo.
Why the study?
Crocin shows cardioprotective potential against chemotherapy-related cardiotoxicity, but clinical evidence for cycle-synchronized intervention remains limited.
Does crocus total glucosides tablets prevent cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy?
RCT (n=120)
Double-blind
1:1
Does crocus total glucosides tablets prevent cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy?
Answers are grounded in this paper and cite their sources.
An 8-day, cycle-synchronized regimen of crocus total glucosides tablets attenuates LVGLS decline and reduces the incidence of cancer therapy-related cardiac dysfunction during breast cancer chemotherapy.
Crocin shows cardioprotective potential against chemotherapy‐related cardiotoxicity, but clinical evidence for cycle‐synchronized intervention remains limited. This randomized, double‐blind, placebo‐controlled trial investigated whether crocus total glucosides tablets (CTGT) administered synchronously with chemotherapy could prevent cancer therapy‐related cardiac dysfunction (CTRCD) in breast cancer patients. A total of 120 patients were randomly assigned (1:1) to receive either CTGT or placebo for 8 days/cycle, starting 1 day before chemotherapy. Primary endpoints were 6‐month relative decline in left ventricular global longitudinal strain (ΔLVGLS%) and change in left ventricular ejection fraction (ΔLVEF); secondary endpoints included 3‐month measures, LVEF and LVGLS, CTRCD incidence [LVEF<50% or ΔLVGLS%>15% or elevated high‐sensitivity cardiac troponin I (hs‐cTnI)/N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP)], and severe arrhythmias. Based on the intention‐to‐treat analysis, CTGT significantly attenuated the 6‐month ΔLVGLS% compared with placebo (−6.55 ± 10.85 vs. −12.63 ± 13.49%, p = 0.009), whereas ΔLVEF did not differ significantly (−3.67 ± 5.75 vs. −2.40 ± 5.47%, p = 0.220). Similar results were observed at 3 months (ΔLVGLS%: −3.91 ± 10.18 vs. −7.76 ± 10.64%, p = 0.047). CTGT also reduced the proportion of patients with ΔLVGLS%>15% (18.3 vs. 40.0%, p = 0.009) and the incidence of CTRCD (21.7 vs 46.7%, p = 0.004). An 8‐day, cycle‐synchronized CTGT regimen attenuates LVGLS decline and reduces CTRCD incidence, highlighting its cardioprotective effect during breast cancer chemotherapy (NCT05504148).
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted an RCT in Breast cancer (n=120). Crocus total glucosides tablets (CTGT) vs. Placebo was evaluated on 6-month relative decline in left ventricular global longitudinal strain (ΔLVGLS%) (p=0.009). Cycle-synchronized crocus total glucosides tablets attenuated the 6-month relative decline in left ventricular global longitudinal strain compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: